サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1788323

RNAターゲット低分子創薬の世界市場

RNA Targeting Small Molecule Drug Discovery

出版日
ページ情報
英文 173 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
RNAターゲット低分子創薬の世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

RNAターゲット低分子創薬の世界市場は2030年までに53億米ドルに達する

2024年に18億米ドルと推定されるRNAターゲット低分子創薬の世界市場は、2024～2030年の分析期間においてCAGR 19.9%で成長し、2030年には53億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるがんは、CAGR18.1％を記録し、分析期間終了時には20億米ドルに達すると予測されます。感染症分野の成長率は、分析期間のCAGRで20.7％と推定されます。

米国市場は4億7,110万米ドルと推定、中国はCAGR19.0％で成長予測

米国のRNAターゲット低分子創薬市場は、2024年に4億7,110万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに8億2,310万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは19.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に17.9%と17.3%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約13.9%で成長すると予測されています。

世界のRNAターゲット低分子創薬市場- 主要動向と促進要因のまとめ

なぜRNAターゲティングが創薬における革命的アプローチとして台頭しているのか？

創薬の分野では、従来のタンパク質ベースの治療薬にとどまらない画期的なアプローチであるRNA標的小分子への注目が高まり、パラダイムシフトが起きています。RNAは遺伝子の発現と制御に重要な役割を果たしており、がん、神経変性疾患、ウイルス感染症など、さまざまな疾患を治療するための魅力的な標的となっています。構造生物学とハイスループットスクリーニング技術の進歩により、RNA構造に選択的に結合できる低分子の同定が可能になり、新たな治療の道が開かれました。二次構造を安定化させたり、RNAとタンパク質の相互作用を阻害したりすることによって、RNAの機能を調節する低分子化合物の能力は、これまで治療不可能であった標的を治療する可能性を開いています。さらに、計算モデリングとAIを駆使した薬剤スクリーニングの開発により、強力なRNA標的化合物の発見が加速しています。RNAに特化したライブラリーとフラグメントベースの創薬アプローチの統合は、この新たな領域の精度と効率をさらに高め、RNA標的治療薬を現代医療における変革的な力として位置づけています。

RNA生物学における最近のブレークスルーは市場拡大をどのように促進しているか？

RNA生物学における最近の動向は、RNA標的低分子医薬品の開発を大きく後押しし、疾患経路へのより正確な介入を可能にしています。リボスイッチ、ロング・ノン・コーディングRNA（lncRNA）、マイクロRNAなどの機能的RNA構造の発見により、治療標的の範囲が広がっています。研究者たちは現在、低温電子顕微鏡（cryo-EM）やNMR分光法などのRNA構造マッピング技術を活用して、極めて特異的な治療可能なRNAモチーフを同定しています。さらに、mRNAワクチンやアンチセンス・オリゴヌクレオチドなどのRNAベースの治療薬の成功は、治療標的としてのRNAの大きな可能性を強調しています。企業は次世代RNAターゲット・ライブラリーへの投資を増やしており、低分子候補化合物のより効果的なスクリーニングと最適化を可能にしています。さらに、RIBOTAC（リボヌクレアーゼ標的キメラ）などのRNA分解技術の出現は、疾患関連RNA配列を選択的に分解する新たな戦略を提供しています。こうしたブレークスルーは、RNAに焦点を当てた創薬の拡大を加速させ、多額の投資を呼び込み、バイオテクノロジー企業と製薬大手との戦略的提携を促進しています。

RNA標的治療薬に対する製薬会社やバイオテクノロジー企業の関心を高めているものは何か？

製薬会社やバイオテクノロジー企業がRNA標的低分子化合物への関心を高めている背景には、アンメット・メディカル・ニーズに対応する革新的な治療薬に対する緊急のニーズがあります。タンパク質を標的とした従来の医薬品開発アプローチでは、特に複雑な遺伝的背景を持つ疾患においては限界がありました。RNA標的分子は、転写レベルに介入することで代替戦略を提供し、有害なタンパク質が合成される前に病気の進行を防ぐ可能性があります。さらに、RNA固有の構造的可塑性により、従来のタンパク質阻害剤に比べ、より多様なターゲティングの機会が得られます。規制当局が新規RNA標的治療薬の早期承認を認めたことで、大手製薬企業はRNAに焦点を当てたパイプラインを積極的に拡大しています。戦略的提携、合併、買収は増加傾向にあり、各社は独自のRNA標的プラットフォームに多額の投資を行っています。低分子は大型のRNAベースの薬剤よりも効率的に細胞に浸透する能力があるため、このアプローチの商業的魅力はさらに高まっています。RNA研究のための資金が増加し続ける中、製薬業界では、希少遺伝性疾患、腫瘍学、感染症への対処を目的としたRNA標的化プログラムが急増しています。

市場を前進させる主な成長促進要因は何か？

RNAターゲット低分子創薬市場の成長は、RNA構造解析の技術的進歩、複雑な疾患の有病率の上昇、革新的な治療薬に対する需要の増加など、いくつかの要因によって牽引されています。ハイスループット・スクリーニング技術の拡大とAIを活用した創薬プラットフォームが相まって、RNA結合分子の同定が大幅に加速しています。さらに、mRNAワクチンなどのRNAベースの治療法の成功は、RNAを標的としたアプローチに対する投資家の信頼を強めています。RNAが疾患進行における重要な制御要素として認識されつつあることが、ノンコーディングRNAや構造化RNAエレメントを標的とする新たな治療戦略の開発に拍車をかけています。製薬業界が個別化医療を推進していることと、RNA治療薬に焦点を当てたバイオテクノロジー新興企業が急増していることが相まって、市場の成長がさらに加速しています。RNA標的戦略が進化を続ける中、RNAに焦点を当てた医薬品開発における戦略的提携、規制当局の支援、画期的な技術革新に支えられ、同市場は採用の増加が見込まれています。

セグメント

適応症（がん、感染症、代謝性疾患、神経疾患、その他）;エンドユーザー（製薬・バイオファーマ企業、学術・研究機関、その他）

調査対象企業の例

  • Accent Therapeutics Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Anima Biotech Inc.
  • Arbutus Biopharma Corporation
  • Arrakis Therapeutics
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Dicerna Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Epics Therapeutics
  • Evotec SE
  • Expansion Therapeutics
  • F. Hoffmann-La Roche Ltd
  • H3 Biomedicine Inc.
  • Ionis Pharmaceuticals Inc.
  • Merck & Co., Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32835

Global RNA Targeting Small Molecule Drug Discovery Market to Reach US$5.3 Billion by 2030

The global market for RNA Targeting Small Molecule Drug Discovery estimated at US$1.8 Billion in the year 2024, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 19.9% over the analysis period 2024-2030. Cancer, one of the segments analyzed in the report, is expected to record a 18.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Infectious Diseases segment is estimated at 20.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$471.1 Million While China is Forecast to Grow at 19.0% CAGR

The RNA Targeting Small Molecule Drug Discovery market in the U.S. is estimated at US$471.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$823.1 Million by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.9% and 17.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global RNA Targeting Small Molecule Drug Discovery Market - Key Trends & Drivers Summarized

Why Is RNA Targeting Emerging As A Revolutionary Approach In Drug Discovery?

The field of drug discovery has witnessed a paradigm shift with the growing focus on RNA-targeting small molecules, a breakthrough approach that extends beyond traditional protein-based therapeutics. RNA plays a critical role in gene expression and regulation, making it an attractive target for treating a wide array of diseases, including cancer, neurodegenerative disorders, and viral infections. Advances in structural biology and high-throughput screening techniques have enabled the identification of small molecules that can selectively bind to RNA structures, offering novel therapeutic avenues. The ability of small molecules to modulate RNA function, either by stabilizing secondary structures or interfering with RNA-protein interactions, has opened up possibilities for treating previously undruggable targets. Additionally, the development of computational modeling and AI-driven drug screening is accelerating the discovery of potent RNA-targeting compounds. The integration of RNA-focused libraries and fragment-based drug discovery approaches is further enhancing the precision and efficiency of this emerging domain, positioning RNA-targeting therapeutics as a transformative force in modern medicine.

How Are Recent Breakthroughs In RNA Biology Driving Market Expansion?

Recent advances in RNA biology have significantly bolstered the development of RNA-targeting small molecule drugs, enabling more precise intervention in disease pathways. The discovery of functional RNA structures, such as riboswitches, long non-coding RNAs (lncRNAs), and microRNAs, has expanded the scope of therapeutic targets. Researchers are now leveraging RNA structural mapping techniques, including cryo-electron microscopy (cryo-EM) and NMR spectroscopy, to identify highly specific druggable RNA motifs. Additionally, the success of RNA-based therapeutics, such as mRNA vaccines and antisense oligonucleotides, has underscored the immense potential of RNA as a therapeutic target. Companies are increasingly investing in next-generation RNA-targeting libraries, enabling more effective screening and optimization of small-molecule candidates. Furthermore, the emergence of RNA degrader technologies, such as RIBOTACs (ribonuclease-targeting chimeras), is providing a novel strategy for selectively degrading disease-associated RNA sequences. These breakthroughs are accelerating the expansion of RNA-focused drug discovery, attracting significant investment and fostering strategic collaborations between biotech firms and pharmaceutical giants.

What Is Fueling The Interest Of Pharma & Biotech Companies In RNA-Targeted Therapies?

The growing interest of pharmaceutical and biotech companies in RNA-targeting small molecules is driven by the urgent need for innovative therapeutics that address unmet medical needs. Traditional drug development approaches targeting proteins have reached limitations, particularly in diseases with complex genetic underpinnings. RNA-targeting molecules offer an alternative strategy by intervening at the transcriptional level, potentially preventing disease progression before harmful proteins are even synthesized. Moreover, RNA’s inherent structural plasticity allows for more diverse targeting opportunities compared to conventional protein inhibitors. With regulatory bodies granting accelerated approvals for novel RNA-targeting therapeutics, major pharma players are actively expanding their RNA-focused pipelines. Strategic collaborations, mergers, and acquisitions are on the rise, with companies investing heavily in proprietary RNA-targeting platforms. The ability of small molecules to penetrate cells more efficiently than larger RNA-based drugs is further driving the commercial appeal of this approach. As funding for RNA research continues to grow, the pharmaceutical sector is witnessing a surge in RNA-targeting programs aimed at addressing rare genetic disorders, oncology, and infectious diseases.

What Are The Key Growth Drivers Propelling The Market Forward?

The growth in the RNA-targeting small molecule drug discovery market is driven by several factors, including technological advancements in RNA structural analysis, the rising prevalence of complex diseases, and the increasing demand for innovative therapeutics. The expansion of high-throughput screening techniques, coupled with AI-powered drug discovery platforms, is significantly accelerating the identification of RNA-binding molecules. Additionally, the success of RNA-based therapies, such as mRNA vaccines, has strengthened investor confidence in RNA-targeted approaches. The growing recognition of RNA as a critical regulatory element in disease progression is fueling the development of new therapeutic strategies targeting non-coding RNAs and structured RNA elements. The pharmaceutical industry's push towards personalized medicine, coupled with a surge in biotech startups focused on RNA therapeutics, is further amplifying market growth. As RNA-targeting strategies continue to evolve, the market is expected to witness increased adoption, backed by strategic collaborations, regulatory support, and breakthrough innovations in RNA-focused drug development.

SCOPE OF STUDY:

The report analyzes the RNA Targeting Small Molecule Drug Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others); End-Use (Pharma & Biopharma Companies, Academic & Research Institutes, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Accent Therapeutics Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Anima Biotech Inc.
  • Arbutus Biopharma Corporation
  • Arrakis Therapeutics
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Dicerna Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Epics Therapeutics
  • Evotec SE
  • Expansion Therapeutics
  • F. Hoffmann-La Roche Ltd
  • H3 Biomedicine Inc.
  • Ionis Pharmaceuticals Inc.
  • Merck & Co., Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • RNA Targeting Small Molecule Drug Discovery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Understanding of RNA Biology Drives Expansion of RNA Targeting Small Molecule Drug Discovery
    • Rising Prevalence of Genetic Disorders and Cancer Expands Market Opportunities for RNA-Based Therapeutic Solutions
    • Technological Advancements in RNA Targeting and Modulation Tools Propel Growth in Small Molecule Drug Discovery
    • Surge in Investment in Precision Medicine Strengthens Business Case for RNA Targeting Small Molecule Drugs
    • Increasing Demand for Targeted Therapies Drives Market Adoption of RNA Modulators in Drug Development
    • Expanding Applications of RNA Targeting in Immuno-Oncology Create New Frontiers for Drug Discovery
    • Integration of AI and Machine Learning in Drug Discovery Accelerates the Identification of RNA Targets
    • Growth of Personalized Medicine Platforms Expands Addressable Market for RNA Targeting Drug Development
    • Rising Focus on Rare Diseases and Undruggable Targets Creates Opportunities for RNA Targeting Small Molecules
    • Increasing Role of RNA in Disease Mechanisms Strengthens Market Adoption of RNA Targeting Therapeutics
    • Regulatory Advancements and Incentives for Rare and Orphan Drug Development Propel RNA Targeting Drug Discovery
    • Surge in Academic and Industry Collaborations Drives Innovation in RNA Targeting Small Molecule Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World RNA Targeting Small Molecule Drug Discovery Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for RNA Targeting Small Molecule Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Metabolic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Metabolic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Metabolic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • RNA Targeting Small Molecule Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for RNA Targeting Small Molecule Drug Discovery by Indication - Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by Indication - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases and Other Indications for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for RNA Targeting Small Molecule Drug Discovery by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of World 15-Year Perspective for RNA Targeting Small Molecule Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION